Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) · Sponsor: Arsenal Biosciences, Inc.
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
This description comes directly from the study's public registry record.
Arsenal Biosciences, Inc. · 650-446-4874 · clinicaltrials@arsenalbio.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) | Aurora, Colorado, United States | Recruiting |
| University of Iowa and Holden Comprehensive Cancer Center | Iowa City, Iowa, United States | Recruiting |
| The University of Kansas Cancer Center | Fairway, Kansas, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Perlmutter Cancer Center - NYU Langone Health | New York, New York, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07285694